Ferrer Internacional S.A. clinical trials
The registry lists 47 studies whose lead sponsor is Ferrer Internacional S.A. or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 47studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Ferrer Internacional S.A. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Ferrer Internacional S.A.’s studies test, most studies first; none is open now — 11 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
1 of Ferrer Internacional S.A.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- 1JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 47 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 709
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 8 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ferrer Internacional S.A..
- Alexza Pharmaceuticals, Inc.23 studies →Acquired — became part of Ferrer Internacional S.A., Jun 2016 · source ↗
Something wrong?
- Ferrer Internacional S.A.21 studiesSame company
Something wrong?
- Ferrer inCode, S.L.1 study →Divested — left Ferrer Internacional S.A., Sep 12, 2018 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 47 of 47.
- Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and EffectivenessRecruitingNCT06499363
- Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung DiseaseAvailableNCT05572996
- A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)CompletedNCT06355531Phase 2
- Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF EpisodesTerminatedNCT05979415Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting SyndromeCompletedNCT04645953Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral SclerosisCompletedNCT05178810Phase 3
- Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisTerminatedNCT05866926Phase 3
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT02090764Phase 3
- Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord InjuryStatus unknownNCT02917291Phase 1/2
- Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's DiseaseCompletedNCT04157933Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)CompletedNCT04065529Phase 3
- Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital SettingCompletedNCT02525991Phase 4
- Staccato® Granisetron Multiple Dose PKCompletedNCT04327765Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Apomorphine Single and Multi Dose PKCompletedNCT03822364Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine Pulmonary Safety in Healthy VolunteersCompletedNCT00789360Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Prochlorperazine Thorough QT/QTcCompletedNCT00543062Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine Single Dose PKCompletedNCT00444028Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Prochlorperazine in Migraine (Out Patient)CompletedNCT00422812Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Prochlorperazine in Migraine (in Clinic)CompletedNCT00610428Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine in Agitation (Proof of Concept)CompletedNCT00369577Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- ADASUVE-Lorazepam Drug-Drug InteractionCompletedNCT01877642Phase 4
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk ScoreCompletedNCT03336463
Sponsor listed in the registry: Ferrer inCode, S.L. · First submitted before Ferrer inCode, S.L. left Ferrer Internacional S.A.
- ADASUVE 2-dose Thorough QT/QTc StudyCompletedNCT01854710Phase 4
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine in Agitated Patients With SchizophreniaCompletedNCT00628589Phase 3
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine in Agitated Patients With Bipolar DisorderCompletedNCT00721955Phase 3
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine in Migraine (in Clinic)CompletedNCT00489476Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Alprazolam in Panic AttackCompletedNCT00477451Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine in Migraine (Out Patient)CompletedNCT00825500Phase 2
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to MonotherapyStatus unknownNCT02791958Phase 2
- Staccato Loxapine PK in Smokers and NonsmokersCompletedNCT00873769Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Fentanyl Single and Multidose PKCompletedNCT00402350Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine Multidose PKCompletedNCT00555412Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine Pulmonary Safety in Patients With AsthmaCompletedNCT00890175Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Zaleplon Single Dose PharmacokineticsCompletedNCT00620620Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Alprazolam Single Dose PKCompletedNCT00444522Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Staccato Loxapine Pulmonary Safety in Patients With COPDCompletedNCT00889837Phase 1
Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT01397461Phase 3
- Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.CompletedNCT00334386Phase 4
- Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) TreatmentCompletedNCT01144286Phase 2
- Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart FailureTerminatedNCT01549158Phase 4
- Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL CholesterolTerminatedNCT01362218Phase 2
- A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) CholesterolTerminatedNCT01004705Phase 2
- A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood PressureTerminatedNCT01005290Phase 2
- Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in ChildrenTerminatedNCT01646580Phase 4
- ICTUS Study: International Citicoline Trial on Acute StrokeTerminatedNCT00331890Phase 3
- Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic LesionsCompletedNCT01005771Phase 2
- Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.CompletedNCT00409942Phase 4